Abstract
The past two decades have been marked by a growing understanding of the co-stimulatory and co-inhibitory pathways that are critical to the generation of an effective, well-regulated immune response. Capitalizing on an increasingly nuanced appreciation for the role that these molecules play in anti-tumor immune responses, a diversity of novel therapies to treat human cancers are being explored. The ground-breaking success of anti-CTLA-4 therapy in the treatment of advanced melanoma has set the stage for the clinical development of agents targeting a diversity of co-stimulatory and co-inhibitory molecules. Herein, we review the co-signaling molecules that regulate T cell activation with a focus on their potential role(s) in anti-tumor immune responses. Where available, pre-clinical and clinical studies evaluating the anti-tumor activity of agents targeting these molecules are presented.
Original language | English (US) |
---|---|
Title of host publication | Cancer Immunotherapy |
Subtitle of host publication | Paradigms, Practice and Promise |
Publisher | Springer New York |
Pages | 211-280 |
Number of pages | 70 |
ISBN (Electronic) | 9781461447320 |
ISBN (Print) | 1461447313, 9781461447313 |
DOIs | |
State | Published - May 1 2013 |
Externally published | Yes |
ASJC Scopus subject areas
- General Medicine